From JPMA On assuming the office of Chairman -Aiming to be a country where innovation thrives
The coronavirus disaster that lasted for three years had a major impact on social life, but thanks to the efforts of many healthcare professionals and the new coronavirus infection (COVID-19) vaccine and therapeutic agents, life before the coronavirus has finally returned. During this period, new ways of working and living have become possible through the use of various digital tools, and in this respect, the coronary disaster seems to have changed the common sense of society.
On the other hand, the lessons we have learned from the coronary disaster are that medicines and vaccines are indispensable in the fight against pandemics, and that measures must be taken even in times of peace from the perspective of national security. In addition to pandemic countermeasures, there are many diseases for which there is still no cure, and pharmaceutical companies must work to create new medicines for these diseases.
The JPMA will not only support academia and start-ups, but will also play a role in nurturing the seeds generated from these efforts to create new drugs originating from Japan. With strong support from the government, if each player has a strong will to establish industry-academia-government collaboration from a new perspective, Japanese drug discovery will accelerate and innovation will flourish.
Japan Pharmaceutical Manufacturers Association
Chairman Hiroaki Ueno
In order for innovation to continue to be generated, it is also important to have a system in which innovation is properly evaluated. This is important not only to encourage the creation of innovation in one's own country, but also to attract innovation from other countries. JPMA is committed to exchanging opinions with stakeholders and making recommendations on policies that should be implemented to create a system in which the value of pharmaceutical products is properly evaluated.
We aim to create a "country where innovation thrives" where motivated companies take on the challenge of addressing unmet needs, innovation is continuously generated, and the value of pharmaceuticals produced is duly evaluated.
(Excerpt from the Chairman's Message on the JPMA website)
Japan Pharmaceutical Manufacturers Association (JPMA)
Japan Pharmaceutical Manufacturers Association (JPMA)
JPMA is a voluntary association of R&D-oriented pharmaceutical companies, established in 1968, with the motto of "realization of patient-participatory medicine," and has contributed to global healthcare through the development of innovative new drugs for ethical use.
JPMA is engaged in a multifaceted program of activities to solve various problems common to the pharmaceutical industry, to deepen understanding of pharmaceuticals, and to promote international collaboration. In addition, we are committed to the sound development of the pharmaceutical industry, particularly by strengthening our policy formulation and advocacy activities, addressing internationalization, and reinforcing our public relations system.
Aiming to contribute to society through the development of new drugs Japan Pharmaceutical Manufacturers Association